ទំព័រដើម › Non-Small Cell Lung Cancer › អូហាយ៉ូ › Columbus
ការសាកល្បងគ្លីនិកសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុង Columbus, OH
ការសិក្សាចំនួន 57 សម្រាប់ Non-Small Cell Lung Cancer កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Columbus (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Mark H Zangmeister Center /ID# 272502, Columbus
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Health Center West, Columbus
- និង 3 ទៀត
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- The Ohio State University, Columbus
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Local Institution - 0176, Columbus
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Ohio State University Comprehensive Cancer Center, Columbus
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- ALX Center 10, Columbus
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 3
- The Ohio State University, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- The Ohio State University Comprehensive Cancer Center, Columbus
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
- OhioHealth Riverside Methodist Hospital, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Local Institution - 0102, Columbus
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University, Columbus
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
កំពុងជ្រើសរើសដំណាក់កាល 3
- Clinical Study Sites, Columbus
- Clinical Study Site, Columbus
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Mark H. Zangmeister Cancer Center, Columbus
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Comprehensive Cancer Center, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University, Columbus
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University, Columbus
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Hospital, Columbus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Ohio State University, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Ohio State University Hospitals, Columbus
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University, Columbus
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
កំពុងជ្រើសរើសដំណាក់កាល 1
- Local Institution - 0045, Columbus
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Ohio State University Comprehensive Cancer Center, Columbus
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Ohio State University Comprehensive Cancer Center, Columbus
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
កំពុងជ្រើសរើស
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University, Columbus
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · ឆ្ងាយ 7 ម៉ាយ
- និង 2 ទៀត
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University Wexner Medical Center, Columbus
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- និង 7 ទៀត
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Memorial Hospital, Marysville · ឆ្ងាយ 27 ម៉ាយ
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Comprehensive Cancer Center, Columbus
GEMINI-NSCLC: NSCLC Biomarker Study
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Ohio State University, Columbus
- OhioHealth Reseach Institute, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University, Columbus
ការសាកល្បងសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 145
- New York City, NYការសិក្សា 121
- Arlington, VAការសិក្សា 104
- Nashville, TNការសិក្សា 97
- Boston, MAការសិក្សា 90
- Los Angeles, CAការសិក្សា 87
- St. Louis, MOការសិក្សា 73
- Chicago, ILការសិក្សា 61
- Baltimore, MDការសិក្សា 60
- San Antonio, TXការសិក្សា 59
- Washington, DCការសិក្សា 55
- Seattle, WAការសិក្សា 53
ការសិក្សាផ្សេងទៀតនៅក្នុង Columbus
- មហារីកទ្រូងការសិក្សា 40
- មហារីកស៊ុតការសិក្សា 39
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 38
- មហារីកសួតការសិក្សា 37
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 35
- ជំងឺលីម្វូស៊ីតប្រចាំការសិក្សា 28
- មហារីកដែលរីករាលដាលការសិក្សា 27
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 25
- មហារីកតូចការសិក្សា 24
- ជំងឺ Multiple Myelomaការសិក្សា 24
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 24
- មេឡាណូម៉ាការសិក្សា 21
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។